454 related articles for article (PubMed ID: 8706727)
21. Binding to human dipeptidyl peptidase IV by adenosine deaminase and antibodies that inhibit ligand binding involves overlapping, discontinuous sites on a predicted beta propeller domain.
Abbott CA; McCaughan GW; Levy MT; Church WB; Gorrell MD
Eur J Biochem; 1999 Dec; 266(3):798-810. PubMed ID: 10583373
[TBL] [Abstract][Full Text] [Related]
22. Aqueous seed extract of Syzygium cumini inhibits the dipeptidyl peptidase IV and adenosine deaminase activities, but it does not change the CD26 expression in lymphocytes in vitro.
Bellé LP; Bitencourt PE; Abdalla FH; Bona KS; Peres A; Maders LD; Moretto MB
J Physiol Biochem; 2013 Mar; 69(1):119-24. PubMed ID: 22798209
[TBL] [Abstract][Full Text] [Related]
23. Expression of CD26 and its association with dipeptidyl peptidase IV activity in lymphocytes of type 2 diabetes patients.
Bellé LP; Bitencourt PE; de Bona KS; Zanette RA; Moresco RN; Moretto MB
Cell Biochem Biophys; 2011 Nov; 61(2):297-302. PubMed ID: 21614532
[TBL] [Abstract][Full Text] [Related]
24. Cleavage by CD26/dipeptidyl peptidase IV converts the chemokine LD78beta into a most efficient monocyte attractant and CCR1 agonist.
Proost P; Menten P; Struyf S; Schutyser E; De Meester I; Van Damme J
Blood; 2000 Sep; 96(5):1674-80. PubMed ID: 10961862
[TBL] [Abstract][Full Text] [Related]
25. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV.
Lambeir AM; Durinx C; Scharpé S; De Meester I
Crit Rev Clin Lab Sci; 2003 Jun; 40(3):209-94. PubMed ID: 12892317
[TBL] [Abstract][Full Text] [Related]
26. CD26/dipeptidyl peptidase IV does not work as an adenosine deaminase-binding protein in rat cells.
Iwaki-Egawa S; Watanabe Y; Fujimoto Y
Cell Immunol; 1997 Jun; 178(2):180-6. PubMed ID: 9225009
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of human immunodeficiency virus type 1 infection in a T-cell line (CEM) by new dipeptidyl-peptidase IV (CD26) inhibitors.
Jiang JD; Wilk S; Li J; Zhang H; Bekesi JG
Res Virol; 1997; 148(4):255-66. PubMed ID: 9272576
[TBL] [Abstract][Full Text] [Related]
28. Truncation of macrophage-derived chemokine by CD26/ dipeptidyl-peptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interaction.
Proost P; Struyf S; Schols D; Opdenakker G; Sozzani S; Allavena P; Mantovani A; Augustyns K; Bal G; Haemers A; Lambeir AM; Scharpé S; Van Damme J; De Meester I
J Biol Chem; 1999 Feb; 274(7):3988-93. PubMed ID: 9933589
[TBL] [Abstract][Full Text] [Related]
29. Characterisation of human dipeptidyl peptidase IV expressed in Pichia pastoris. A structural and mechanistic comparison between the recombinant human and the purified porcine enzyme.
Bär J; Weber A; Hoffmann T; Stork J; Wermann M; Wagner L; Aust S; Gerhartz B; Demuth HU
Biol Chem; 2003 Dec; 384(12):1553-63. PubMed ID: 14719797
[TBL] [Abstract][Full Text] [Related]
30. Characterization of dipeptidyl peptidase IV (CD26) from human lymphocytes.
De Meester I; Vanhoof G; Hendriks D; Demuth HU; Yaron A; Scharpé S
Clin Chim Acta; 1992 Sep; 210(1-2):23-34. PubMed ID: 1358482
[TBL] [Abstract][Full Text] [Related]
31. CD26 antigen is a surface dipeptidyl peptidase IV (DPPIV) as characterized by monoclonal antibodies clone TII-19-4-7 and 4EL1C7.
Ulmer AJ; Mattern T; Feller AC; Heymann E; Flad HD
Scand J Immunol; 1990 Apr; 31(4):429-35. PubMed ID: 1970666
[TBL] [Abstract][Full Text] [Related]
32. Identification of the target of monoclonal antibody A6H as dipeptidyl peptidase IV/CD26 by LC MS\MS.
Hass GM; Meyer JL; Newitt RA; Labuda T; Brown L; Aebersold R; Vessella RL
Hybridoma; 2001 Aug; 20(4):231-6. PubMed ID: 11604108
[TBL] [Abstract][Full Text] [Related]
33. Dipeptidyl peptidase IV (CD26) activity in human alloreactive T cell subsets varies with the stage of differentiation and activation status.
Ruiz P; Hao L; Zucker K; Zacharievich N; Viciana AL; Shenkin M; Miller J
Transpl Immunol; 1997 Jun; 5(2):152-61. PubMed ID: 9269038
[TBL] [Abstract][Full Text] [Related]
34. Human thymocyte dipeptidyl peptidase IV (CD26) activity is altered with stage of ontogeny.
Ruiz P; Zacharievich N; Hao L; Viciana AL; Shenkin M
Clin Immunol Immunopathol; 1998 Aug; 88(2):156-68. PubMed ID: 9714693
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of CD26/dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients.
Korom S; De Meester I; Stadlbauer TH; Chandraker A; Schaub M; Sayegh MH; Belyaev A; Haemers A; Scharpé S; Kupiec-Weglinski JW
Transplantation; 1997 May; 63(10):1495-500. PubMed ID: 9175816
[TBL] [Abstract][Full Text] [Related]
36. Effect of deoxycoformycin and Val-boroPro on the associated catalytic activities of lymphocyte CD26 and ecto-adenosine deaminase.
Jeanfavre DD; Woska JR; Pargellis CA; Kennedy CA; Prendergast J; Stearns C; Reilly PL; Barton RW; Bormann BJ
Biochem Pharmacol; 1996 Dec; 52(11):1757-65. PubMed ID: 8986139
[TBL] [Abstract][Full Text] [Related]
37. Expression, purification, and characterization of human dipeptidyl peptidase IV/CD26 in Sf9 insect cells.
Dobers J; Zimmermann-Kordmann M; Leddermann M; Schewe T; Reutter W; Fan H
Protein Expr Purif; 2002 Aug; 25(3):527-32. PubMed ID: 12182835
[TBL] [Abstract][Full Text] [Related]
38. Good or evil: CD26 and HIV infection.
Ohtsuki T; Tsuda H; Morimoto C
J Dermatol Sci; 2000 Apr; 22(3):152-60. PubMed ID: 10698152
[TBL] [Abstract][Full Text] [Related]
39. Influence of dipeptidyl peptidase IV on enzymatic properties of adenosine deaminase.
Sharoyan S; Antonyan A; Mardanyan S; Lupidi G; Cristalli G
Acta Biochim Pol; 2006; 53(3):539-46. PubMed ID: 16929383
[TBL] [Abstract][Full Text] [Related]
40. CD26/dipeptidyl peptidase IV: a regulator of immune function and a potential molecular target for therapy.
Aytac U; Dang NH
Curr Drug Targets Immune Endocr Metabol Disord; 2004 Mar; 4(1):11-8. PubMed ID: 15032621
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
